Connect Sign In
Next generation sequencing (NGS) testing detects UBA1 gene mutations, which are essential for the diagnosis of VEXAS syndrome and concurrent hematologic neoplasms.
ARUP medical directors will present key hematopathology research at the 66th ASH Annual Meeting, including developments in systemic mastocytosis treatment and testing for myeloid malignancy mutations.
ARUP medical directors and scientists presented key molecular pathology advancements at AMP 2024 on topics such as viral load prediction, automated DNA extraction, and parasite detection.
ARUP has developed a first-of-its-kind myeloid malignancy mutation panel that offers both genomewide copy number variant (CNV)/copy number-neutral loss of heterozygosity (CN-LOH) and targeted gene analysis in a single assay, providing disease-defining information that informs patient care.
FDA leaders answered questions on artificial intelligence (AI), international regulations, and representation in clinical trials during the Utah Life Sciences Summit.
The University of Utah Licensing and Technology Office awards recognize impactful research and innovation. Though retired, Wittwer is active in advancing molecular diagnostics and mentoring others.
A new, first-of-its-kind test uses blood-based biomarkers to assess the risk of developing preeclampsia with severe features and facilitates appropriate interventions.
Benjamin T. Bradley, MD, PhD, was awarded a grant to study the use of a self-collection blood sample device to increase access to hepatitis C virus testing in rural Utah counties.
ARUP medical directors will present at the 2024 Association of Medical Laboratory Immunologists (AMLI) Annual Meeting on emerging topics in the field.
The new Sherrie Perkins Research and Innovation Collaboration Grant, designed to foster collaboration in healthcare, will fund cutting-edge research in lab medicine that could impact patient care.
